Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Abstract: Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi.

Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

Abstract: Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.

Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

Abstract: A process for the surface treatment of a metal part comprises: exposing a surface (1) of the metal part to a stream of substantially spherical particles, so that any portion of said surface receives said particles along several primary incidences, the primary incidences of the particles on a portion of the surface being essentially distributed in a cone or a conical film which has an outer half apex angle between 10° and 45°, until a surface layer (3) of nanostructures having an average thickness of several tens of microns is obtained, the particles having a diameter of less than 2 mm and greater than 0.1 mm and being projected at a speed between 40 m/s and 100 m/s. A thermochemical treatment is then applied, in particular a low-temperature treatment of the nitriding type or a high-temperature treatment of the low-pressure carbonitriding type.

Abstract: The present invention relates to a method for diagnosing a carcinoma or a residual disease associated thereto, or for the prognosis of a carcinoma, or for monitoring the effectiveness of an anti-tumour therapy directed against a carcinoma, or for monitoring the follow-up of an individual affected by a carcinoma, in particular colorectal carcinoma, carcinoma of the stomach, mammary carcinoma, pulmonary carcinoma or carcinoma of the prostate, carcinoma of the liver, carcinoma of the ovary, carcinoma of the kidney, carcinoma of the thyroid, carcinoma of the bladder or carcinoma of the pancreas. The method of the invention consists in placing adult stem cells in contact with a sample of a haemo-derivative of the individual to be analyzed and in verifying the expression of at least an epithelial marker in the stem cells by means of immunofluorescence, immunohistochemistry, ELISA or RT-PCR.

Abstract: A process for the surface treatment of a metal part comprises: exposing a surface (1) of the metal part to a stream of substantially spherical particles, so that any portion of said surface receives said particles along several primary incidences, the primary incidences of the particles on a portion of the surface being essentially distributed in a cone or a conical film which has an outer half apex angle between 10° and 45°, until a surface layer (3) of nanostructures having an average thickness of several tens of microns is obtained, the particles having a diameter of less than 2 mm and greater than 0.1 mm and being projected at a speed between 40 m/s and 100 m/s. A thermochemical treatment is then applied, in particular a low-temperature treatment of the nitriding type or a high-temperature treatment of the low-pressure carbonitriding type.

Abstract: The present invention relates to a method for diagnosing a carcinoma or a residual disease associated thereto, or for the prognosis of a carcinoma, or for monitoring the effectiveness of an anti-tumour therapy directed against a carcinoma, or for monitoring the follow-up of an individual affected by a carcinoma, in particular colorectal carcinoma, carcinoma of the stomach, mammary carcinoma, pulmonary carcinoma or carcinoma of the prostate, carcinoma of the liver, carcinoma of the ovary, carcinoma of the kidney, carcinoma of the thyroid, carcinoma of the bladder or carcinoma of the pancreas. The method of the invention consists in placing adult stem cells in contact with a sample of a haemo-derivative of the individual to be analysed and in verifying the expression of at least an epithelial marker in the stem cells by means of immunofluorescence, immunohistochemistry, ELISA or RT-PCR.

Abstract: Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-?, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.

Abstract: The invention concerns an image acquisition apparatus comprising a UV radiation source (29) capable of making fluorescent supports (1) whereof the images are to be acquired, a window (21) transparent to UV and visible light, typically rectangular, for receiving an image support to be acquired, a linear sensor (31) whereof the length is preferably substantially equal to the width of the window receiving a support and means (23) driving the sensor and, preferably the UV radiation source parallel to one of the edges of the window (21) receiving an image support. The invention is mainly applicable to image acquisition for revealing a chemical or physical phenomenon. The invention is mainly applicable to planar chromatography or layer chromatography.

Abstract: A joint for toothed belt aimed at conveying articles, with the belt including an inner central layer, which defines the belt body, an upper layer, which defines a surface for receiving articles to be conveyed, and a lower layer featuring teeth, includes: first connecting mechanism, attached in an irremovable way to the central layer in the area of the terminal section of a belt first edge to be joined; second connecting mechanism, attached irremovably to the central layer in the area of the terminal section of a belt second edge to be joined. After the first edge had been moved close to the second edge to complete a closed loop formed by the belt, the first connecting mechanism and second connecting mechanism engage with each other and are reciprocally locked in a removable way by locking mechanism, acting crosswise to the belt in the area of the central layer, to join the first edge and second edge.

Abstract: A joint for toothed belt aimed at conveying articles, with the belt including an inner central layer, which defines the belt body, an upper layer, which defines a surface for receiving articles to be conveyed, and a lower layer featuring teeth, includes: first connecting means, attached in an irremovable way to the central layer in the area of the terminal section of a belt first edge to be joined; second connecting means, attached irremovably to the central layer in the area of the terminal section of a belt second edge to be joined. After the first edge had been moved close to the second edge to complete a closed loop formed by the belt, the first connecting means and second connecting means engage with each other and are reciprocally locked in a removable way by locking means, acting crosswise to the belt in the area of the central layer, to join the first edge and second edge.

Abstract: Apparatus for freeze-drying products comprises an enclosure within which mounted shelves provided with cooling and heating means and in which vessels for containing the products are located.These shelves are arranged in two series, viz a first series maintained at a temperature lower than 0.degree. C. and a second series maintained at a temperature higher than 0.degree. C. in operation and a transfer mechanism is incorporated to cause the vessels to travel from the shelves of the first series to those of the second series, the enclosure being under vacuum.The invention is applicable for the freeze-drying of food products, biological substances, among others.